The dopamine-related polymorphisms BDNF, COMT, DRD2, DRD3, and DRD4 are not linked with changes in CSF dopamine levels and frequency of HIV infection

• Published in: Journal of Neural Transmission 2017-04, Vol.124 (4), p.501-509
• Main Authors: Horn, Anne, Scheller, C., du Plessis, S., Burger, R., Arendt, G., Joska, J., Sopper, S., Maschke, C. M., Obermann, M., Husstedt, I. W., Hain, J., Riederer, P., Koutsilieri, E.
• Format: Article
• Language: English
• Subjects: Adult; Biomarkers - cerebrospinal fluid; Brain-Derived Neurotrophic Factor - genetics; Catechol O-Methyltransferase - genetics; CD4 Lymphocyte Count; Cohort Studies; Dopamine - cerebrospinal fluid; Female; Gene Frequency; Genotyping Techniques; Germany; HIV Infections - cerebrospinal fluid; HIV Infections - genetics; Humans; Lentivirus; Male; Medicine; Medicine & Public Health; Middle Aged; Neurology; Neuropsychological Tests; Neurosciences; Polymorphism, Genetic; Psychiatry; Psychiatry and Preclinical Psychiatric Studies - Original Article; Receptors, Dopamine - genetics; Retroviridae; Risk; Severity of Illness Index; South Africa; Viral Load
• ISSN: 0300-9564; 1435-1463
• DOI: 10.1007/s00702-016-1659-6

We showed previously that higher levels in CSF dopamine in HIV patients are associated with the presence of the dopamine transporter (DAT) 10/10-repeat allele which was also detected more frequently in HIV-infected individuals compared to uninfected subjects. In the current study, we investigated further whether other genetic dopamine (DA)-related polymorphisms may be related with changes in CSF DA levels and frequency of HIV infection in HIV-infected subjects. Specifically, we studied genetic polymorphisms of brain-derived neurotrophic factor, catechol- O -methyltransferase, and dopamine receptors DRD2, DRD3, and DRD4 genetic polymorphisms in uninfected and HIV-infected people in two different ethnical groups, a German cohort (Caucasian, 72 individuals with HIV infection and 22 individuals without HIV infection) and a South African cohort (Xhosan, 54 individuals with HIV infection and 19 individuals without HIV infection). We correlated the polymorphisms with CSF DA levels, HIV dementia score, CD4 + T cell counts, and HIV viral load. None of the investigated DA-related polymorphisms was associated with altered CSF DA levels, CD4 + T cell count, viral load, and HIV dementia score. The respective allele frequencies were equally distributed between HIV-infected patients and controls. Our findings do not show any influence of the studied genetic polymorphisms on CSF DA levels and HIV infection. This is in contrast to what we found previously for the DAT 3′UTR VNTR and highlights the specific role of the DAT VNTR in HIV infection and disease.